Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) EBIT Margin (2017 - 2025)

VYNE Therapeutics' EBIT Margin history spans 9 years, with the latest figure at 7542.0% for Q2 2025.

  • For Q2 2025, EBIT Margin fell 234400.0% year-over-year to 7542.0%; the TTM value through Jun 2025 reached 8452.38%, down 194563.0%, while the annual FY2025 figure was 5219.12%, 350828.0% up from the prior year.
  • EBIT Margin reached 7542.0% in Q2 2025 per VYNE's latest filing, down from 4598.5% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 3234.58% in Q2 2021 to a low of 27531.03% in Q4 2022.
  • Average EBIT Margin over 5 years is 8104.55%, with a median of 6405.49% recorded in 2022.
  • Peak YoY movement for EBIT Margin: tumbled -2429074bps in 2022, then skyrocketed 1854156bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 3240.29% in 2021, then crashed by -750bps to 27531.03% in 2022, then skyrocketed by 67bps to 8989.47% in 2023, then crashed by -71bps to 15385.54% in 2024, then soared by 51bps to 7542.0% in 2025.
  • Per Business Quant, the three most recent readings for VYNE's EBIT Margin are 7542.0% (Q2 2025), 4598.5% (Q1 2025), and 15385.54% (Q4 2024).